2 Dividend Aristocrats to Buy for 2023

Heading into next year, a couple of Aristocrats that look to be good investments are Abbott Laboratories (NYSE: ABT) and ExxonMobil (NYSE: XOM). Healthcare giant Abbott Laboratories has a diverse business that generates over $1 billion in revenue every quarter from multiple segments, including medical devices, pharmaceuticals, diagnostics, and nutrition. Abbott has since restarted production and, assuming no interruptions happen again, next year should be a stronger one for that segment as well.